Zoryve is under clinical development by Arcutis Biotherapeutics and currently in Pre-Registration for Psoriasis.

Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...

New data reveals that longer-term lebrikizumab treatment significantly improves outcomes for patients with moderate-to-severe atopic dermatitis who didn’t meet response criteria by week 16.

ATOPIC dermatitis (AD), a chronic inflammatory skin condition, affects millions globally and is linked to systemic immune ...

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...

The following is a summary of “Fungal Head and Neck Dermatitis: Current Understanding and Management,” published in the July ...

Inflammation is a crucial part of the body's defense mechanism, playing a key role in fighting infections and repairing ...

Corvus Pharmaceuticals (CRVS) stock was granted a new buy recommendation by H.C. Wainwright based on its lead asset, despite its recent selloff. Read more here.

The following is a summary of “Skin Microbiome in the First Year of Life and Its Association With Atopic Dermatitis,” ...

H.C. Wainwright initiated coverage of Corvus Pharmaceuticals (CRVS) with a Buy rating and $11 price target Corvus is a clinical-stage ...